Arkolith/Insider Trading/KNSA/Form 4

Tessari Eben

CHIEF OPERATING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Dec 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$501K
Net Open-Market Flow
-$501K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)6K$8.83$53K29K
Dec 15, 2025Sell(S)12K$41.56$501K17K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 15, 2025Option exercise(M)6K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001867899-25-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML